Last reviewed · How we verify
Ipratropium + Levosalbutamol Free Dose Combination
Ipratropium + Levosalbutamol Free Dose Combination is a Combination bronchodilator (anticholinergic + beta-2 agonist) Small molecule drug developed by Neutec Ar-Ge San ve Tic A.Ş. It is currently in Phase 3 development for Acute bronchospasm in chronic obstructive pulmonary disease (COPD), Asthma exacerbation, Reversible airway obstruction.
This combination uses an anticholinergic bronchodilator (ipratropium) and a short-acting beta-2 agonist (levosalbutamol) to relax airway smooth muscle through complementary pathways.
This combination uses an anticholinergic bronchodilator (ipratropium) and a short-acting beta-2 agonist (levosalbutamol) to relax airway smooth muscle through complementary pathways. Used for Acute bronchospasm in chronic obstructive pulmonary disease (COPD), Asthma exacerbation, Reversible airway obstruction.
At a glance
| Generic name | Ipratropium + Levosalbutamol Free Dose Combination |
|---|---|
| Sponsor | Neutec Ar-Ge San ve Tic A.Ş |
| Drug class | Combination bronchodilator (anticholinergic + beta-2 agonist) |
| Target | Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Ipratropium blocks muscarinic acetylcholine receptors on airway smooth muscle, preventing bronchoconstriction, while levosalbutamol (the active R-enantiomer of albuterol) stimulates beta-2 adrenergic receptors to promote bronchodilation. Together, they provide rapid and sustained airway opening through dual mechanisms, commonly used in acute and chronic obstructive airway disease management.
Approved indications
- Acute bronchospasm in chronic obstructive pulmonary disease (COPD)
- Asthma exacerbation
- Reversible airway obstruction
Common side effects
- Tremor
- Tachycardia
- Headache
- Palpitations
- Dry mouth
- Nervousness
Key clinical trials
- Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE3)
- Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE3)
- Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ipratropium + Levosalbutamol Free Dose Combination CI brief — competitive landscape report
- Ipratropium + Levosalbutamol Free Dose Combination updates RSS · CI watch RSS
- Neutec Ar-Ge San ve Tic A.Ş portfolio CI
Frequently asked questions about Ipratropium + Levosalbutamol Free Dose Combination
What is Ipratropium + Levosalbutamol Free Dose Combination?
How does Ipratropium + Levosalbutamol Free Dose Combination work?
What is Ipratropium + Levosalbutamol Free Dose Combination used for?
Who makes Ipratropium + Levosalbutamol Free Dose Combination?
What drug class is Ipratropium + Levosalbutamol Free Dose Combination in?
What development phase is Ipratropium + Levosalbutamol Free Dose Combination in?
What are the side effects of Ipratropium + Levosalbutamol Free Dose Combination?
What does Ipratropium + Levosalbutamol Free Dose Combination target?
Related
- Drug class: All Combination bronchodilator (anticholinergic + beta-2 agonist) drugs
- Target: All drugs targeting Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor
- Manufacturer: Neutec Ar-Ge San ve Tic A.Ş — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Acute bronchospasm in chronic obstructive pulmonary disease (COPD)
- Indication: Drugs for Asthma exacerbation
- Indication: Drugs for Reversible airway obstruction
- Compare: Ipratropium + Levosalbutamol Free Dose Combination vs similar drugs
- Pricing: Ipratropium + Levosalbutamol Free Dose Combination cost, discount & access